WEBULL
WebtradeDownload

Where Does Baxter International (BAX) Valuation Stand As Latest Results Reset The Debate?

Simply Wall St · 2d ago

Baxter International (BAX) recently posted Q2 FY26 results, reporting US$2.96b in revenue and US$126m in earnings. That update now anchors how investors look at the stock’s returns and valuation.

Recent trading tells a mixed story. Baxter International’s share price has risen 22.92% year to date and 6.72% over 90 days. However, the 1-year total shareholder return of 5.57% contrasts with a much weaker 3-year total shareholder return, which has fallen 22.59%, and a 5-year total shareholder return that has dropped 66.45%. This points to improving short-term momentum against a tougher long-run record.

Spot fresh ideas alongside Baxter International’s recent momentum by scanning a curated set of healthcare and value-driven opportunities in the 29 high quality undervalued stocks.

Baxter International’s rebound and fresh earnings progress raise a simple issue. After this move, does the balance of risk and potential reward still tilt in favour of new buyers, once valuation is laid out in full?

Most Popular Narrative: 17% Undervalued

Baxter International closed at $23.97 while the widely followed narrative framework points to a fair value near $28.73, so the current debate hinges on whether recent execution can close that gap.

Baxter International focus on decentralization and the Baxter Growth & Performance System, with hundreds of completed and ongoing continuous improvement events tied to divisional KPIs, is intended to tighten cost control and execution. This approach may support higher operating margins and stronger free cash flow over time.

Allocation of more resources toward higher value areas such as Advanced Surgery, drug compounding and connected care platforms like Connex 360, Dynamo, IQX and PeerVue is shifting Baxter International mix toward businesses that management is targeting for faster growth. If that mix shift continues, it could lift consolidated revenue and earnings.

See why 19 investors see Baxter International as 17% undervalued.

Result: Fair Value of $28.73 (UNDERVALUED)

Still, Baxter International faces real pressure if Novum IQ pump issues drag on or if supply constraints in injectables keep hospital related earnings under strain.

Find out about the key risks to this Baxter International narrative.

Next Steps

Mixed feelings on Baxter International after these results are fair, and the fastest way to cut through that noise is to inspect the evidence yourself, weigh both the risks and rewards, then review the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Baxter International?

Do not stop with Baxter International. Broaden your watchlist with focused stock ideas that match different goals, from value and resilience to fresh opportunities with solid fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.